Sugi Predict

Sugi Predict / Compounds / SCHEMBL4448665

SCHEMBL4448665

SCHEMBL4448665

Clc1cc(Cl)c2c(c1)N=C1CCCCCN1C2

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 15/20 0.66
▸ BCHE P06276 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ KLK7 P49862 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29869033 1.00 ACHE (0.66) ACHEBCHEALDH1A1MEN1USP2
Hydrochloric Acid SCHEMBL8968390 0.99 ACHE (0.64) ACHEBCHEALDH1A1MEN1USP2
SCHEMBL8969421 0.98 ACHE (0.63) ACHEBCHEALDH1A1MEN1USP2
SCHEMBL8968233 0.94 ACHE (0.57) ACHEBCHEALDH1A1MEN1USP2
Hydrochloric Acid SCHEMBL8969536 0.93 ACHE (0.56) ACHEBCHEALDH1A1MEN1USP2
SCHEMBL8969695 0.86 ACHE (0.59) ACHEBCHEALDH1A1MEN1USP2
SCHEMBL8969971 0.86 ACHE (0.63) ACHEBCHEALDH1A1MEN1USP2
SCHEMBL8968320 0.86 ACHE (0.63) ACHEBCHEALDH1A1MEN1USP2
SCHEMBL8969149 0.86 ACHE (0.59) ACHEBCHEALDH1A1MEN1USP2
SCHEMBL8969128 0.86 ACHE (0.59) ACHEBCHEALDH1A1MEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090036487-A1 Combinations PFIZER INC. 2009-02-05 — — US claimed
EP-1667722-A1 COMBINATIONS OF ALPHA-2-DELTA LIGANDS AND ACETYLCHOLINESTERASE INHIBITORS Pfizer Limited (GB) 2006-06-14 — — EP claimed
WO-2005027975-A1 COMBINATIONS OF ALPHA-2-DELTA LIGANDS AND ACETYLCHOLINESTERASE INHIBITORS PFIZER LIMITED (GB) 2005-03-31 — — WO claimed
US-20050065176-A1 Combinations FIELD MARK JOHN (GB) 2005-03-24 — — US claimed
US-5486512-A LEARNING ENHANCEMENT WARNER-LAMBERT COMPANY (US) 1996-01-23 — — US claimed
EP-0597956-A1 QUINAZOLINE DERIVATIVES AS ACETYLCHOLINESTERASE INHIBITORS WARNER-LAMBERT COMPANY (US) 1994-05-25 — — EP claimed
WO-1993003034-A1 QUINAZOLINE DERIVATIVES AS ACETYLCHOLINESTERASE INHIBITORS WARNER-LAMBERT COMPANY (US) 1993-02-18 — — WO claimed
US-11160785-B2 Methods and compositions for improving cognitive function AGENEBIO INC. (US) 2021-11-02 — — US disclosed
EP-2968220-B1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION AGENEBIO INC (US) 2021-05-05 — — EP disclosed
US-20180015109-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2018-01-18 — — US disclosed
US-20160271108-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION AGENEBIO, INC. 2016-09-22 — — US disclosed
EP-2533645-B1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2016-07-27 — — EP disclosed
EP-2968220-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION Agenebio, Inc. (US) 2016-01-20 — — EP disclosed
WO-2005112946-A1 METHOD FOR IMPROVING COGNITIVE FUNCTION BY CO-ADMINISTRATION OF A GABAB RECEPTOR ANTAGONIST AND AN ACETYLCHOLINESTERASE INHIBITOR THE JOHNS HOPKINS UNIVERSITY (US) 2005-12-01 — — WO disclosed
WO-2005041653-A2 SYNERGISTIC FUNGICIDAL ACTIVE COMBINATIONS BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2005-05-12 — — WO disclosed
WO-2005027975-A1 COMBINATIONS OF ALPHA-2-DELTA LIGANDS AND ACETYLCHOLINESTERASE INHIBITORS PFIZER LIMITED (GB) 2005-03-31 — — WO disclosed
US-20050065176-A1 Combinations FIELD MARK JOHN (GB) 2005-03-24 — — US disclosed
US-5486512-A LEARNING ENHANCEMENT WARNER-LAMBERT COMPANY (US) 1996-01-23 — — US disclosed
EP-0597956-A1 QUINAZOLINE DERIVATIVES AS ACETYLCHOLINESTERASE INHIBITORS WARNER-LAMBERT COMPANY (US) 1994-05-25 — — EP disclosed
WO-1993003034-A1 QUINAZOLINE DERIVATIVES AS ACETYLCHOLINESTERASE INHIBITORS WARNER-LAMBERT COMPANY (US) 1993-02-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036487-A1 Combinations CHRNE, CHRND, CHRNG ACHE 7/4885BCHE 40/4885ALDH1A1 4325/4885
US-20160271108-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, BACE1, GRIN2A ACHE 4/4885BCHE 29/4885ALDH1A1 1226/4885
US-11160785-B2 Methods and compositions for improving cognitive function BACE2, BACE1, GRIN2A ACHE 4/4885BCHE 29/4885ALDH1A1 1226/4885
US-20180015109-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE ACHE 3/4885BCHE 47/4885ALDH1A1 2614/4885
US-20050065176-A1 Combinations CHRNE, CHRND, CHRNG ACHE 7/4885BCHE 40/4885ALDH1A1 4325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.